AnGes, Inc.
Announcement of Completion of Subject Enrollment in the Early Phase 2 Clinical Trial of Co-developed Tie2 Receptor Agonist (AV-001)
Announced completion of subject enrollment for the co-developed product AV-001 in the early phase 2 clinical trial. Progresses to data analysis in a disease area granted FDA Fast Track designation; no direct impact on consolidated results for the fiscal year ending December 2026.
Key Figures
- Completion of subject enrollment (early phase 2): Unknown
- FDA Fast Track designation: Stated (assumed)
- Impact on consolidated results for the fiscal year ending December 2026: Unknown
AI要約
Key Points
AnGes, Inc. announced that subject enrollment has been completed in the early phase 2 clinical trial of AV-001, co-developed with Vasomune Therapeutics. This is an important milestone in the progress of a clinical trial targeting ARSD-related diseases, and the program will proceed to the data analysis phase. There is no impact on the consolidated results for the fiscal year ending December 2026 from this matter.
Outlook and Impact for Investors
With AV-001 having received FDA Fast Track designation, completion of subject enrollment will accelerate data collection and analysis. Preparations toward obtaining topline results are expected to advance, and in the medium to long term the product's market potential and progress in clinical evaluation could change its valuation. However, at this time the financial impact is unknown and further disclosures may be necessary.
AnGes, Inc.
Company overview · Stock price · Financial data · All IR
